Alkahest has commenced a Phase ll trial of GRF6019 to treat patients with mild to moderate Alzheimer’s disease.

The randomised double-blinded response study has also dosed its first patient with GRF6019, a plasma-derived product currently under investigation for the treatment of neurodegenerative diseases.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Safety, tolerability, and feasibility of GRF6019 infusions in patients with mild to moderate Alzheimer’s disease will be analysed during the new ALK6019-201 trial.

The trial expects to enrol 40 patients, who will be randomised to receive one of two GRF6019 doses.

“In various preclinical studies, the product has reportedly demonstrated its ability to improve patient’s motor and cognitive performance, as well as histological correlates.”

Alkahest president and CEO Karoly Nikolich said: “Based on the promising data from our PLasma for Alzheimer SymptoM Amelioration (PLASMA) study last year, we have progressed the development of GRF6019, a proprietary plasma fraction developed and provided by Grifols, our development and clinical partner.”

GRF6019 has been manufactured by Spain-based human plasma protein therapeutics solution provider Grifols.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In various preclinical studies, the product has reportedly demonstrated its ability to improve patient’s motor and cognitive performance, as well as histological correlates.

Alkahest chief medical officer Sam Jackson said: “As the population ages, the number of people with Alzheimer’s disease and other neurodegenerative diseases will increase sharply, precipitating an urgent need for innovative therapies.

“GRF6019 has demonstrated encouraging preclinical results, including improvements in cognitive and histological measures compared to previously evaluated whole plasma, and has the potential to address this growing unmet need for an effective treatment for Alzheimer’s disease.”

Alkahest is primarily involved in developing treatments for age-related diseases, with an emphasis on neurodegeneration.